Literature DB >> 27975249

Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo.

Julia E Gerson1,2, Urmi Sengupta1,2, Rakez Kayed3,4,5.   

Abstract

Tau oligomers have been shown to be the main toxic tau species in a number of neurodegenerative disorders. In order to study tau oligomers both in vitro and in vivo, we have established methods for the reliable preparation, isolation, and detection of tau oligomers. Methods for the seeding of tau oligomers, isolation of tau oligomers from tissue, and detection of tau oligomers using tau oligomer-specific antibodies by biochemical and immunohistochemical methods are detailed below.

Entities:  

Keywords:  Amyloid seeding; Tau oligomer isolation; Tau oligomers; Tauopathies

Mesh:

Substances:

Year:  2017        PMID: 27975249     DOI: 10.1007/978-1-4939-6598-4_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

1.  Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.

Authors:  Georg Nübling; M Schuberth; K Feldmer; A Giese; L M Holdt; D Teupser; S Lorenzl
Journal:  Exp Brain Res       Date:  2017-05-10       Impact factor: 1.972

2.  TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.

Authors:  Mauro Montalbano; Salome McAllen; Filippa Lo Cascio; Urmi Sengupta; Stephanie Garcia; Nemil Bhatt; Anna Ellsworth; Eric A Heidelman; Omar D Johnson; Samantha Doskocil; Rakez Kayed
Journal:  Neurobiol Dis       Date:  2020-10-14       Impact factor: 5.996

3.  Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target.

Authors:  Jian-Lan Gu; Fei Liu
Journal:  Curr Med Sci       Date:  2021-01-11

4.  The role of wild-type tau in Alzheimer's disease and related tauopathies.

Authors:  Chih Hung Lo; Jonathan N Sachs
Journal:  J Life Sci (Westlake Village)       Date:  2020-12

Review 5.  Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies.

Authors:  Alice Bittar; Urmi Sengupta; Rakez Kayed
Journal:  NPJ Vaccines       Date:  2018-02-27       Impact factor: 7.344

6.  Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits.

Authors:  Balaji Krishnan; Rakez Kayed; Giulio Taglialatela
Journal:  Alzheimers Dement (N Y)       Date:  2018-02-14

7.  AAV2-mediated GRP78 Transfer Alleviates Retinal Neuronal Injury by Downregulating ER Stress and Tau Oligomer Formation.

Authors:  Yonju Ha; Wei Liu; Hua Liu; Shuang Zhu; Fan Xia; Julia E Gerson; Nisha A Azhar; Ronald G Tilton; Massoud Motamedi; Rakez Kayed; Wenbo Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-09-04       Impact factor: 4.799

8.  Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.

Authors:  Julia E Gerson; Kathleen M Farmer; Natalie Henson; Diana L Castillo-Carranza; Mariana Carretero Murillo; Urmi Sengupta; Alan Barrett; Rakez Kayed
Journal:  Mol Neurodegener       Date:  2018-03-15       Impact factor: 14.195

9.  A role for tau in learning, memory and synaptic plasticity.

Authors:  Fabrizio Biundo; Dolores Del Prete; Hong Zhang; Ottavio Arancio; Luciano D'Adamio
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

10.  P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer's disease.

Authors:  Kathleen M Farmer; Gaurav Ghag; Nicha Puangmalai; Mauro Montalbano; Nemil Bhatt; Rakez Kayed
Journal:  Acta Neuropathol Commun       Date:  2020-08-10       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.